



Media Release

Medienmitteilung

Communiqué aux Médias

Sandoz Inc. 506  
Carnegie Center Drive  
Suite 400 Princeton, NJ  
08540  
Phone +1 609 627 8500  
Fax +1 609 627 8682  
[www.us.sandoz.com](http://www.us.sandoz.com)

### **Sandoz launches authorized generic version of Lamisil®**

**Princeton, New Jersey; July 2, 2007** -- Sandoz introduced terbinafine hydrochloride, a generic version of Lamisil®, in the U.S. today. This product is being launched as an authorized generic upon the expiration of patent protection on the original Novartis drug.

Sandoz is marketing terbinafine hydrochloride, which is used to treat fungal nail infections, in 250 mg tablets. Sales of Lamisil in the U.S. were approximately \$685 million for the 12 months ending April 2007.

#### **About Sandoz**

Sandoz, a division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 840 compounds in over 5,000 forms worldwide and sells its products in more than 110 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these drugs along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to the strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (U.S.). In 2006, Sandoz employed approximately 21,000 people worldwide and posted sales of USD 6 billion.

#### **Disclaimer**

The foregoing release may contain forward-looking statements regarding potential additional marketing approvals or future sales of terbinafine hydrochloride. Any such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with terbinafine hydrochloride to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that terbinafine hydrochloride will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. Management's expectations regarding terbinafine hydrochloride could be affected by various risks and factors referred to in the company's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.



\* \* \*

**For further information**

Sandoz US Communications:

Charles A. Bruns

609.627.8881

Lamisil® is a registered trademark of Novartis.